Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Sunday, September 14, 2014

Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog

Biogen Idec Inc. ( BIIB ) announced encouraging two-year data from the phase III ADVANCE study which evaluated the efficacy, safety and tolerability of Plegridy in patients suffering from relapsing-remitting multiple sclerosis (RRMS). 

Post-hoc analyses of the two-year data from the study confirmed that Plegridy's positive effects on reducing disease activity and disability progression were maintained in the second year of the study. 

A significantly higher proportion of patients receiving Plegridy in both the years demonstrated no evidence of disease activity (absence of clinical and MRI disease activity) over two years of treatment as compared to those who switched to Plegridy from placebo. Additionally, significant reductions in the risk of 24-week confirmed disability progression was observed in patients receiving Plegridy for a two-year period as compared to patients treated with placebo in the first year. 

We believe that the positive two-year data from the ADVANCE study will boost both physicians' and patients' confidence in Plegridy. 

Read more 

 Keep CURRENT and up to date, with MS News and Information
Sign-up for emails 



No comments: